Literature DB >> 21822543

Protein kinase Cδ in tumorigenesis of human malignant fibrous histiocytoma.

Naomasa Fukase1, Teruya Kawamoto, Kenta Kishimoto, Hitomi Hara, Yoshiyuki Okada, Yasuo Onishi, Mitsunori Toda, Masahiro Kurosaka, Toshihiro Akisue.   

Abstract

Protein kinase Cδ (PKCδ), an isoform of PKC, has been shown to act as a critical mediator of tumor progression and apoptosis; however, its role in musculoskeletal tumors is still unknown. In the current study, we examined the expression of PKCδ in human musculoskeletal tumor tissue samples, and investigated the effects of siRNA downregulation of PKCδ on human malignant fibrous histiocytoma (MFH) cell proliferation, migration, and apoptosis, to elucidate its functional roles in musculoskeletal tumorigenesis. Of note, real-time PCR analysis revealed that mRNA expression of PKCδ in high-grade musculoskeletal MFH tumors was significantly lower than that in benign schwannomas. siRNA downregulation of PKCδ significantly increased human MFH cell proliferation and migration, and markedly suppressed apoptosis. These findings suggest that PKCδ has a negative effect on tumorigenesis and/or acts as a pro-apoptotic kinase in human MFH cells. The data presented here could be applied in the development of new therapeutic avenues, with the elevation of PKCδ expression being one potential strategy to prevent MFH progression. Thus, PKCδ may be a potent therapeutic target for human MFH.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21822543     DOI: 10.3892/or.2011.1415

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  4 in total

Review 1.  Protein kinase C and cancer: what we know and what we do not.

Authors:  R Garg; L G Benedetti; M B Abera; H Wang; M Abba; M G Kazanietz
Journal:  Oncogene       Date:  2013-12-16       Impact factor: 9.867

Review 2.  Multifunctional roles of PKCδ: Opportunities for targeted therapy in human disease.

Authors:  Mary E Reyland; David N M Jones
Journal:  Pharmacol Ther       Date:  2016-05-11       Impact factor: 12.310

3.  TMBIM6/BI-1 contributes to cancer progression through assembly with mTORC2 and AKT activation.

Authors:  Hyun-Kyoung Kim; Kashi Raj Bhattarai; Raghu Patil Junjappa; Jin Hee Ahn; Suvarna H Pagire; Hyun Ju Yoo; Jaeseok Han; Duckgue Lee; Kyung-Woon Kim; Hyung-Ryong Kim; Han-Jung Chae
Journal:  Nat Commun       Date:  2020-08-11       Impact factor: 14.919

4.  Transcriptional activation of PRMT5 by NF-Y is required for cell growth and negatively regulated by the PKC/c-Fos signaling in prostate cancer cells.

Authors:  Huan-Tian Zhang; Dabao Zhang; Zhen-Gang Zha; Chang-Deng Hu
Journal:  Biochim Biophys Acta       Date:  2014-10-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.